Compare
Inhibitor Therapeutics, Inc. vs Vaccinex, Inc. vs Lipella Pharmaceuticals Inc. vs Artelo Biosciences, Inc.
| Latest fiscal year | Inhibitor Therapeutics, Inc. INTI | Vaccinex, Inc. VCNXLast annual report: year ended 2024-12-31 | Lipella Pharmaceuticals Inc. LIPOLast annual report: year ended 2024-12-31 | Artelo Biosciences, Inc. ARTL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2024-12-31 | 2024-12-31 | 2025-12-31 |
| Revenue | n/a | $601.0K | $536.4K | n/a |
| Revenue growth (YoY) | n/a | +5.4% | +19.3% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | -947.2% | n/a |
| Net margin | n/a | n/m | -935.2% | n/a |
| Net income | -$3.30M | -$18.63M | -$5.02M | -$12.88M |
| EPS (Diluted) | -$0.02 | -$8.88 | -$4.79 | -$12.52 |
| Operating cash flow | -$3.23M | -$16.19M | -$3.95M | -$8.52M |
| Free cash flow | n/a | -$16.21M | n/a | n/a |
| Cash & equivalents | $2.38M | $1.11M | $2.18M | $600.0K |
| Total assets | $2.51M | $2.60M | $2.67M | $2.80M |
| Total liabilities | $3.80M | $5.08M | $754.4K | $4.07M |
| Shareholders' equity | -$1.29M | -$2.49M | $1.92M | -$1.27M |
| Return on year-end equity | n/a | n/a | -261.3% | n/a |
| Shares outstanding | 172.57M | 2.68M | 1.21M | 2.02M |
Revenue, most recent five fiscal years
| Fiscal year | Inhibitor Therapeutics, Inc. | Vaccinex, Inc. | Lipella Pharmaceuticals Inc. | Artelo Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2021-12-31 | $601.0K Ended 2024-12-31 | $536.4K Ended 2024-12-31 | n/a |
| 1 year earlier | $0 Ended 2020-12-31 | $570.0K Ended 2023-12-31 | $449.6K Ended 2023-12-31 | n/a |
| 2 years earlier | $0 Ended 2019-12-31 | $275.0K Ended 2022-12-31 | $184.2K Ended 2022-12-31 | n/a |
| 3 years earlier | $0 Ended 2018-12-31 | $900.0K Ended 2021-12-31 | $259.3K Ended 2021-12-31 | n/a |
| 4 years earlier | $0 Ended 2017-12-31 | $625.0K Ended 2020-12-31 | n/a | n/a |